Publications

  • Krochmal M, van Kessel KEM, Zwarthoff EC, Belczacka I, Pejchinovski M, Vlahou A, Mischak H, Frantzi M.

Urinary peptide panel for prognostic assessment of bladder cancer relapse.

Sci Rep. 2019 May 21;9(1):7635.

 

  • Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J.

CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.

Br J Cancer. 2019 May 16.

 

  • Latosinska A, Siwy J, Mischak H, Frantzi M.

Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future.

Electrophoresis. 2019 May 3.

 

  • Frantzi M, Mischak H, Latosinska A.

Clinical Proteomics on the Path Toward Implementation: First Promises Delivered.

Proteomics Clin Appl. 2019 Mar;13(2):e1800094.

 

  • Frantzi M, Latosinska A, Mischak H.

Proteomics in Drug Development: The Dawn of a New Era?

Proteomics Clin Appl. 2019 Mar;13(2):e1800087.

 

  • Frantzi M, Latosinska A, Belczacka I, Mischak H.

Urinary proteomic biomarkers in oncology: ready for implementation?

Expert Rev Proteomics. 2018 Nov 9:1-15.

 

  • Belczacka I, Pejchinovski M, Krochmal M, Magalhães P, Frantzi M, Mullen W, Vlahou A, Mischak H, Jankowski V.

Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers.

Proteomics Clin Appl. 2019 May;13(3):e1800111.

 

  • Latosinska A, Frantzi M, Merseburger AS, Mischak H.

Promise and Implementation of Proteomic Prostate Cancer Biomarkers.

Diagnostics (Basel). 2018 Aug 29;8(3). pii: E57.

 

  • Belczacka I, Latosinska A, Metzger J, Marx D, Vlahou A, Mischak H, Frantzi M.

Proteomics biomarkers for solid tumors: Current status and future prospects.

Mass Spectrom Rev. 2019 Jan;38(1):49-78.

 

  • Frantzi M, Latosinska A, Kontostathi G, Mischak H.

Clinical Proteomics: Closing the Gap from Discovery to Implementation.

Proteomics. 2018 Jul;18(14):e1700463.

 

  • Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Urinary CE-MS peptide marker pattern for detection of solid tumors.

Sci Rep. 2018 Mar 27;8(1):5227.

 

  • Marx D, Metzger J, Pejchinovski M, Gil RB, Frantzi M, Latosinska A, Belczacka I, Heinzmann SS, Husi H, Zoidakis J, Klingele M, Herget-Rosenthal S.

Proteomics and Metabolomics for AKI Diagnosis.

Semin Nephrol. 2018 Jan;38(1):63-87.

 

  • Latosinska A, Frantzi M, Vlahou A, Merseburger AS, Mischak H.

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.

Proteomics Clin Appl. 2018 Mar;12(2).

 
 
 
 
BioMedBC is a Marie Sklodowska Curie Actions (MSCA) Individual Fellowship programme (H2020-MSCA-IF-2016)
funded by the European Union under the Horizon2020 Framework Programme (Grant Agreement:752755) and
coordinated by Mosaiques diagnostics